Checkpoint Therapeutics (CKPT) investor relations material

Executive summary

• FDA approved UNLOXCYT (cosibelimab-ipdl) in December 2024 as the first and only anti-PD-L1 therapy for advanced cutaneous squamous cell carcinoma (cSCC), marking the company's first commercial product.

• Entered into a definitive merger agreement with Sun Pharmaceutical Industries, valuing the transaction up to $416 million, with shareholders to receive $4.10 per share in cash plus a contingent value right of up to $0.70; closing expected in Q2 2025.

• Company remains a majority-controlled subsidiary of Fortress Biotech, Inc.

• Special stockholder meeting to vote on the merger scheduled for May 28, 2025.

Financial highlights

• Net loss for Q1 2025 was $11.2 million ($0.19 per share), compared to $10.9 million ($0.33 per share) in Q1 2024.

• Cash and cash equivalents increased to $33.0 million as of March 31, 2025, from $6.6 million at year-end 2024, primarily due to warrant exercises.

• Research and development expenses decreased to $3.8 million from $8.5 million year-over-year, mainly due to lower manufacturing and clinical costs post-UNLOXCYT approval.

• General and administrative expenses rose to $7.4 million from $2.5 million, driven by merger-related legal and advisory costs and higher stock-based compensation.

• Weighted average shares outstanding increased to 59.8 million in Q1 2025 from 32.9 million in Q1 2024.

Outlook and guidance

• Cash runway expected to fund operations into Q1 2026, assuming no further warrant exercises.

• Merger with Sun Pharma expected to close in Q2 2025, subject to regulatory and stockholder approval.

• Management anticipates continued operating losses and the need for additional capital if the merger does not close.

• Research and development expenses projected to remain stable for the remainder of 2025; general and administrative expenses expected to increase pending merger outcome.

• Anticipated commercial launch and availability of UNLOXCYT for approved indications.